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Abstract: Multimodal spectral histopathology (MSH), an optical technique combining tissue 
auto-fluorescence (AF) imaging and Raman micro-spectroscopy (RMS), was previously 
proposed for detection of residual basal cell carcinoma (BCC) at the surface of surgically-
resected skin tissue. Here we report the development of a fully-automated prototype 
instrument based on MSH designed to be used in the clinic and operated by a non-specialist 
spectroscopy user. The algorithms for the AF image processing and Raman spectroscopy 
classification had been first optimised on a manually-operated laboratory instrument and then 
validated on the automated prototype using skin samples from independent patients. We 
present results on a range of skin samples excised during Mohs micrographic surgery, and 
demonstrate consistent diagnosis obtained in repeat test measurement, in agreement with the 
reference histopathology diagnosis. We also show that the prototype instrument can be 
operated by clinical users (a skin surgeon and a core medical trainee, after only 1-8 hours of 
training) to obtain consistent results in agreement with histopathology. The development of 
the new automated prototype and demonstration of inter-instrument transferability of the 
diagnosis models are important steps on the clinical translation path: it allows the testing of 
the MSH technology in a relevant clinical environment in order to evaluate its performance 
on a sufficiently large number of patients. 
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1. Introduction 
Basal cell carcinoma (BCC) is the most common cancer type in humans. More than 100,000 
cases of BCC are diagnosed each year in the UK (1.7 million in the USA, and 300,000 in 
Australia) [1]. Patients expect their BCCs to be treated effectively in a single operation, with 
minimal risk of tumor recurrence, and the best cosmetic result possible. Most BCCs (>80%) 
occur on the head and neck areas, in particular the upper central part of the face [2]. The 
majority of these BCCs are treated by wide-local excision performed under local anesthesia in 
an outpatient setting. The treatment outcome of wide-local excision depends on the 
characteristics of the tumor (subtype, location), as well as how well the surgeon can identify 
its spread. For example, a 4 mm surgical margin for primary well-defined BCC measuring 
less than 20mm ensures a complete clearance of over 95% [3] while a 3mm margin, even for 
lesions that measure 6 × 5 mm, will clear only about 85% of tumors [4,5]. Large BCCs 
(>2cm) and those occurring at high risk sites (nose, ear, eyelid, eyebrow, and temple) are at 
higher risk of incomplete treatment, and Mohs micrographic surgery is preferred [6–8]. In 
Mohs surgery, sequential layers of tissue are excised and microscopically examined as frozen 
sections to make sure that all cancer is removed; if residual cancer is present, then the exact 
location of those cells is recorded and further layers of skin tissue are removed until margins 
are clear. Although wide-local excision is the most common surgical technique for treating 
BCC, histopathological confirmation of complete removal takes 1-2 weeks. Incomplete 
removal requires specialist follow-up or a second operation to remove the residual cancer 
(typically by Mohs surgery), which can lead to patient anxiety and poorer cosmetic outcome, 
especially if a skin graft from the initial treatment needs to be redone. Although Mohs surgery 
is typically recommended for high-risk BCCs [9], this complex surgery requires specialist 
surgeon and treatment facilities, and is labor intensive, needing dedicated technicians to 
prepare frozen tissue sections. 
Several technologies have been developed recently to allow microscopic assessment of 
tumor clearance during BCC surgery, including confocal microscopy (CM) [10,11], optical 
coherence tomography (OCT) [12,13] and Raman micro-spectroscopy [14]. While CM and 
OCT enable diagnosis of BCC based on structural features, Raman spectroscopy can measure 
endogenous molecular differences between healthy skin tissue and BCC, with high chemical 
specificity [14–18]. Therefore, Raman spectroscopy offers the prospect of objective diagnosis 
based on quantitative molecular analysis of tissue, which has the potential to reduce intra- and 
inter-user variability, as well as diagnosis subjectivity [19, 20]. Although Raman 
spectroscopy is typically slow to allow imaging of cm-scale tissue samples within time-scales 
compatible with intra-operative use (e.g. <1 hour), selective-sampling Raman spectroscopy 
techniques have been recently developed to reduce measurement time [14, 21]. Our team has 
developed a multimodal spectral imaging technique that integrates tissue auto-fluorescence 
imaging and Raman microscopy that can be used during tissue conserving surgery for fast and 
objective detection of residual tumor [14, 22–24]. Using laboratory instruments, that partially 
included input from user (manual focusing and change of objectives when switching between 
auto-fluorescence and Raman modalities), previous studies demonstrated the feasibility to 
obtain quantitative diagnosis images based on molecular analysis of tissue combined with 
multivariate classification models. 
Here, we report the development of a fully-automated prototype instrument based on the 
combined auto-fluorescence (AF) and Raman micro-spectroscopy (RMS) multimodal 
approach, that allows fully automated measurements of skin surgical resections and objective 
diagnosis of residual BCC. The instrument has been designed and built to fit into clinical 
practice as an alternative to current practice of microscopic histological assessment of frozen 
tissue sections for checking the completeness of BCC removal during all BCC surgery. First, 
we show that the optimized algorithms for analysis of the AF images and Raman 
classification models developed on a laboratory instrument can be successfully transferred on 
the fully automated new device. This is an important step because inter-instrument 
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transferability remains one of the key challenges in the clinical translation of Raman 
spectroscopy. Secondly, we present a model for establishing a threshold based the MSH 
diagnosis image that allows a binary diagnosis at a tissue sample level: margins clear of BCC 
detected: Yes/No. Finally, we investigated the consistency and validity of the MSH diagnosis 
by comparing the MSH assessment output in repeat test measurements recorded by a 
spectroscopy specialist user and clinical users (Mohs surgeon and medical trainee), on a range 
of skin samples excised during Mohs micrographic surgery, and using histopathology as the 
standard of reference. 
2. Methods 
2.1 Tissue samples 
Skin tissue samples were obtained during Mohs micrographic surgery at the Nottingham 
University Hospitals National Health Service (NHS) Trust and the Nottingham NHS 
Treatment Centre. Ethical approval was granted by the Nottingham Research Ethics 
Committee (07/H0408/172) and informed consent was obtained from all patients. After 
excision by the surgeon, the tissue layer was embedded within optimal cutting temperature 
medium (OCT) and frozen with a cryogenic spray (Frostbite, Surgipath). For each tissue 
sample, a 10 μm section (called adjacent section) was cut and stained by hematoxilin and 
eosin (H&E) and used as the standard of reference. The remaining tissue block was then 
defrosted, washed and kept frozen at −20°C until used for Raman spectral measurements. 
In this study, samples from 80 patients with basal cell carcinoma on the face and neck 
were included. The sample set was divided into a training set (50 samples, 30 patients) that 
was measured on the Laboratory Instrument in order to train and optimize the diagnosis 
algorithms. All the samples in the training set were used for the training of the Raman 
classification model, but only the BCC positive samples (35 samples, 23 patients) were used 
for optimization of the algorithms for AF image segmentation and sampling points 
generation. The test set consisted of 47 samples from new 40 patients, which were measured 
on the Prototype instrument to determine the performance of the algorithms. As with the 
samples recorded with the Laboratory Instrument, all test samples were used in the testing of 
Raman classification model, while only the BCC positive samples were used to validate the 
AF algorithms (32 samples, 27 patients). Then, 10 samples (9 patients, no overlap with the 
training or test sets) were used to test the overall performance of the MSH diagnosis on the 
Prototype device, including illustration of intra- and inter-user repeatability. 
2.2 Instrumentation 
Laboratory Instrument. The instrument consisted of an inverted optical microscope (Eclipse-
Ti Nikon) with an automated sample stage (H107 with Proscan II controller, Prior Scientific), 
60 × /1.2NA objective (RiverD International), 785nm laser (IPS, power 100 mW at sample 
surface), spectrometer (RiverD International HPR) equipped with a deep-depletion back-
illuminated cooled CCD (DU401-A-BR-DD, Andor Technology). The acquisition time for 
the Raman measurements ranged between 0.5 and 3 seconds per position. 
Prototype instrument. The instrument was developed jointly by University of Nottingham 
and RiverD International. The requirements and specifications for the clinical application 
were established through consultation with 3 general dermatologists, 23 skin surgeons 
(including Mohs and plastic surgeons) and 4 histopathologists. Its operation at all analysis 
steps was fully automated (see Fig. 1(b), 1(c)). The instrument was designed to analyse skin 
specimens of up to 2cm × 2cm in size (thickness up to 5mm), which would accommodate the 
whole excision surface of most resection specimens in Mohs surgery (including simultaneous 
analysis of up to 4 skin samples fitting the 2cm × 2cm area). The samples used in this study 
represented halves or quarters of spare skin samples resected during Mohs surgery. The 
samples were placed in purpose-designed disposable cassettes. After loading of the cassette in 
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the instrument, a colour image of the sample is displayed on the screen to confirm the correct 
position of the tissue samples and to allow the user to identify the red and blue dye markings 
used for orientation of the tissue with respect to the surgical opening. The software included 
automated calibration, quality control checks and autofocusing of the Raman measurements. 
After the input of the required patient data, the user can start the analysis of the tissue by 
selecting the “Start” button. No additional input is required from the user to reach the final 
diagnosis. The software provides real time display of the AF images and presents the final 
MSH diagnosis as a colour-coded image. 
2.3 Data post-processing and analysis 
Auto-fluorescence imaging: Auto-fluorescence images of the tissue samples were acquired by 
stitching 16 image tiles (6.4mm x 6.4mm) to create a 2cm × 2cm image. The region of the 
image containing tissue was identified automatically and separated from the background by 
using a set intensity threshold. The AF image was then flattened with a rotationally 
symmetric Gaussian low pass filter to minimize fluctuations in intensity and stitching 
artefacts. The segmentation of the resulting AF image was then performed using an intensity 
thresholding based on the optimization described in Section 3. 
Raman spectroscopy. All Raman spectra were corrected for cosmic rays and were 
calibrated using a neon-argon light source and a PMMA sample, and corrected for the 
wavelength dependent sensitivity of the set up using a NIST calibration standard. Background 
signals from optical elements in the instrument were subtracted from the spectra. Spectra 
were then interpolated in the range of 400-1800 cm−1 to 2 cm−1 data spacing. For the training 
data set, raster scans were performed on the surface of the removed tissue samples, adjacent 
to the H&E section. Spectra were acquired with a 0.5 s exposure time and were averaged with 
a 3x3 moving average filter. Spectra were utilized in the classification model only if their 
signal to noise ratio (SNR) was above 15, where SNR was calculated as the ratio between the 
height of the CH2 peak at 1450 cm−1 (local linear baseline subtracted) and rms value of the 
noise in the empty spectral region 1750-1800 cm−1. For the test set, the Raman spectra were 
acquired with the Prototype instrument with a modified version of the MSH procedure that 
allowed acquisition of a larger number of spectra for each sample. To maximize the number 
of Raman spectra to be included in the test set, the minimum number of spectra per segment 
was increased to 20 and the total number of spectra acquired per tissue sample was limited to 
1200. The integration time was set to 3 s per spectrum and spectra with SNR lower than 7 
were discarded. Spectral features (areas of Raman bands) were calculated from the Raman 
spectra of both training and test samples using a local linear background subtraction for each 
band, and were then the normalized to unit norm on a per spectrum basis. 
2.4 MSH diagnosis 
The MSH algorithm generated the diagnosis of each segment obtained by the AF 
segmentation algorithm independently using the Raman spectra measured inside the segment 
in an automated two-step process. In the first round, Raman spectra were measured at the 
locations determined by the sampling point generation algorithm (spectra with SNR lower 
than 4 were discarded). More sampling points were generated to allow new Raman spectra to 
be measured in the second stage of the MSH procedure, to replace the spectra that are 
discarded. Segments for which more than 80% of the spectra were discarded, were labelled 
“Unclassified” (no more spectra were measured for these segments in the second round). The 
retained spectra were denoised based on an independent set of Raman spectra (100,000 
spectra collected from samples in the training set that were not included in the training set 
because the SNR was between 10 and 15) using principal component analysis (PCA) with 50 
PCs [25]. Then, each Raman spectrum was classified by applying the Raman classification 
model. If the segment contained no spectra classified as BCC and the class of all spectra was 
the same, the segment was labelled accordingly. In cases in which the segment contained 
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spectra from more than one class (but no BCC) within a segment, a nearest neighbour 
evaluation was performed within the segment for each of the sampling points and the segment 
was split into regions of nearest proximity for each sampling point location, as described 
previously [22]. If the segment contained only one BCC spectrum, the spectrum was ignored 
and the segment was labelled as above. If more than 80% of spectra were classified as BCC, 
the segment was labelled as BCC. If a segment had at least two spectra classified as BCC, but 
this accounted to less than 80% of the total number of spectra in the segment, a second round 
of Raman spectra were acquired for the segment. For each segment included in the second 
round, the number of sampling points was equal to the number in the first round, and were 
uniformly distributed in the segment (the locations of the first round were taken into account 
to avoid measurements at the same locations). The spectra in the second round were retained 
only if they pass the SNR threshold. The Raman spectra obtained from the two rounds of 
measurements were then joined and were classified using the Raman classification model. 
The results of the classification model were then interpreted on a per spectrum basis and the 
final labelling of each segment was performed using the nearest neighbor method described 
above. The final MSH diagnosis image was generated using a color code for each class. 
3. Results 
MSH provides molecular analysis of skin tissue specimens excised during BCC surgery 
without requiring any additional preparation steps. The aim is to obtain an image of the tissue 
that highlights the residual BCC at the surface of the resected specimen, using color-coded 
labels that indicate the tumour (Fig. 1(a)). Based on this image, the surgeon can make an 
objective decision whether to excise further tissue at the location indicated by the color-coded 
image or whether to stop the surgery. 
 
Fig. 1. a). Schematic description of the intended use of MSH for checking completeness of 
tumour removal during BCC surgery (Mohs surgery and wide-local excision). b) Flow chart 
describing the automated measurement and diagnosis algorithms for MSH. c) Photographs of 
the manual Laboratory Instrument and the automated MSH Prototype. The tissue specimen is 
loaded in a purpose-built cassette with a quartz bottom window (2.5mm x 2.5cm, 1mm thick). 
The cassette is manually placed on the microscope stage of the Laboratory Instrument or 
loaded into the Prototype Instrument. 
3.1 Optimisation of the measurement and diagnosis algorithms based on the 
laboratory Instrument 
In order to achieve reliable and objective diagnosis of BCC, the complete workflow (Fig. 
1(b)) must be invariant across the range of samples obtained in BCC surgery, and be 
transferable between instruments. In this way, once the algorithms have been optimised on 
one device, they can be transferred to all devices deployed in clinics. Thus, every step in the 
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diagnosis workflow described in Fig. 1(b) was first optimised using a training set of samples 
analysed on the Laboratory instrument, for which the user was able to manually adjust the 
focusing and changing the objectives when switching between the AF and Raman 
measurements (Fig. 1(c) left). The algorithms were then tested using a new set of independent 
skin samples analysed on a fully automated Prototype, for which the user operation required 
only the loading of the tissue specimen. 
3.1.1 Segmentation algorithms for the auto-fluorescence imaging 
After the acquisition of the AF image of a skin sample, the entire image was segmented using 
an intensity threshold. However, because the AF images exhibit large inter-sample variations 
in intensity (caused by inter-patient variations in tissue depending on age, anatomic location, 
or pathology, potential laser intensity fluctuations), we developed a user-independent 
algorithm that optimises the value of the intensity threshold for each individual image. To 
quantify the performance of this algorithm, two metrics were defined: 
 ( )
(  )
(  )
Area detected BCC
Area detected BCC Area missed BCC
ρ =
+
  
This metric was calculated for all BCC positive samples in order to measure the fraction of 
the tumour detected and retained by the segmented AF image. 
  (  )
 (  )  (  )
Area Healthy tissue
Area detected BCC Area Healthy tissue
ε =
+
  
The metric ε was calculated for each segment in an AF image containing BCC in order to 
estimate the histological heterogeneity of the segments. The values of Area(detected BCC), 
Area(missed BCC) and Area(Healthy tissue) were obtained by comparing the generated 
segmentation maps with the AF annotated images (manually marking the BCC regions on the 
AF images based on the adjacent H&E sections). Based on a set of comparable adjacent H&E 
sections, we estimate that the use of adjacent H&E sections for the annotation can lead to 
errors of ~10-100μm because of differences in tumour morphology between the tissue 
analysed by AF and the H&E sections. Thus, ρ  and ε  are not an absolute measure of the 
performance of the segmentation algorithm to detect BCC, but rather offer an indication of 
how different methods of segmentation perform comparatively. 
For an ideal segmentation algorithm, the entire tumour is retained for Raman spectroscopy 
analysis, Area(missedBCC) = 0, equivalent to 1ρ = . In addition, all segments containing 
BCC would not contain any healthy tissue, Area(Healthy) = 0, equivalent to 0ε = . Figure 2 
presents some examples of segmentation results for typical skin tissue samples containing 
infiltrative and micro-nodular BCC. Figure 2(a) shows that the tumour regions have lower AF 
intensity compared to the stroma. Two functions were proposed for providing optimal 
segmentation thresholds invariant to the absolute intensity of the AF images: fA = N, where N 
is the number of segments in the segmented image, fB = N*A, where A is area fraction 
captured by the segments in the image. Figure 2(b) shows that both functions fA and fB have a 
global maximum when plotted as a function of the intensity threshold. Figure 2(c) presents 
the segmented AF images when the threshold used corresponded to the maximum values of 
functions fA and fB. For both samples, using the threshold value fB leads to a higher value of 
both ρ  and ε  compared to when using the fA value. These results indicate that fB increases 
the fraction of tumour detected, but also increases the histological heterogeneity of the 
segment (i.e. the amount of healthy tissue within the segments containing BCC also 
increased). 
The statistical analysis of the segmentation parameters ρ  and ε , obtained when using 
different thresholds for AF images of all BCC positive samples in the training set is presented 
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in Fig. 2(d). The results show that using the maximum of the function fB (MaxfB) for selecting 
the optimal intensity threshold for segmentation provides a high detection rate for BCC ( ρ = 
0.3-1, median value 0.7), while ε  ranged between 0.1 and 0.9 (median 0.7). Using the 
maximum of the function fA (MaxfA) provided slightly lower values of ε  ( ε  = 0.1-1, median 
value 0.5), but the value of ρ  also decreased to a median value of 0.35 (range of 0-0.9). 
Because from a clinical point of view the sensitivity is more important than specificity, the 
segmentation algorithm was set to use the threshold value generated by the function fb as it 
increased the capture probability for BCC. 
 
Fig. 2. Optimisation and evaluation of segmentation algorithms for AF images of skin samples 
(recorded on Laboratory Instrument). a)-c) two typical examples: a) AF images; b) 
segmentation optimisation functions: fA = N, where N = segment number; fB = N*A, where A = 
area fraction captured by segments; c) segmentation images and quality parameters 
corresponding to the AF when using the MaxfA (A) and MaxfB (B) as intensity thresholds. Scale 
bars: 5mm. d) Statistical analysis of parameters ρ  and ε  based on AF images recorded on 
the Laboratory Instrument on 35 tissue samples with BCC (23 patients). 
Once the segmentation method was fixed, we evaluated the performance of the algorithm 
for generating sampling points for Raman spectroscopy measurements within the segments of 
the AF images. We employed a method that allocates a minimum number Nmin of sampling 
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points for all segments, with additional sampling points allocated to segments based on their 
area and variance in AF intensity [22]: 
 ( ) [ ]1
( ) ( )
( ) ( )
sampling min restk
i
Var i Area iN i N N
Var i Area i
=
×
= + ×
×   
where ( )samplingN i  is the total number of sampling points allocated to the segment i, Nmin is 
the minimum number of sampling points for each segment, k is the total number of segments, 
Var(i) is the intensity variance in the segment i, Area(i) is the area of the segment i, and Nrest 
= Nsampling, total –k × Nmin is the additional sampling points that can be allocated to segments 
after the allocation of the minimum number of sampling points required for each segment. In 
this study, we used Nmin = 5 and Nsampling total = 800. Using this method for allocating the 
number of sampling points Nsampling(i), two methods were investigated for determining the 
locations of the sampling points within each segment of the image. The first method placed 
sampling points at the locations with the lowest and highest intensity in the segment, followed 
by uniform distribution of the remaining sampling points (Configuration 1). The second 
method generated the sampling points uniformly within the segments (Configuration 2). 
Then, for each sample containing BCC, the tumour “Hit rate” was calculated as the ratio of 
the number of sampling points hitting BCC to the total number of sampling points allocated 
to segments containing BCC. 
 
Fig. 3. Evaluation of sampling points for Raman spectroscopy based on segmentation of AF 
images (Config. 2). Sample 1: typical sample containing BCC, Sample 2: the sample with the 
highest number of segments with BCC missed by the allocated sampling points. a) AF images; 
b) segmented images and sampling points using uniform distribution: pink points represent 
Raman measurements performed on healthy tissue and white points represent Raman 
measurements performed on BCC. The number of segments containing BCC detected and 
missed are indicated for each sample; Scale bars: 5mm. c) evaluation of tumour “Hit rate” and 
missed segments for: sampling points allocated selectively: sampling point at the position of 
the lowest and highest intensity within each segment, and uniform distribution of the 
remaining sampling points (Config. 1); sampling points distributed uniformly within segments 
(Config. 2). 
Figure 3 presents examples of two skin samples containing BCC and the statistical 
analysis for all BCC positive samples in the training set. Figure 3(a), 3(b) show that ρ  was 
~0.50 for both samples, and the BCC regions were effectively detected in both samples: 75 
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and 58 segments containing BCC were detected in Sample 1 and Sample 2 respectively, and 
80-83% of the sampling points within these segments coincided with the location of the 
tumour. Sample 2 was the sample with the highest number of missed segments with BCC in 
the entire training set (8 in Config. 1 and 6 in Config. 2). Figure 3(c) presents the statistical 
analysis of the BCC “Hit rate” and number of missed BCC segment for all tissue samples in 
the training set. The results show that both methods for generating locations of sampling 
points yield similar values for the BCC “hit rate” (0-0.9, median 0.6). Nevertheless, allocating 
sampling points uniformly within each segment provided a lower number of segments in 
which BCC regions were missed (0-2, median 0) compared to Configuration 1 (0-4, median 
1). Based on this results, Config. 2 was selected for the final MSH algorithm. 
3.1.2 Classification model for BCC based on the Raman spectroscopy 
measurements 
After completing the method of generating the sampling locations for Raman spectroscopy, 
MSH requires a classification method whereby each location in the tissue is classified (BCC 
or non-BCC) according to the Raman spectrum measured at the corresponding location. The 
first step for the Raman spectral classification model is the development of a database of 
Raman spectra measured by raster scanning and annotated using histology as a standard of 
reference. The Raman raster scan data were first analyzed by k-means clustering, which 
groups spectra into regions with similar spectra, allocating each spectrum to the cluster with 
the nearest mean and as such performs a rough delineation between groups of spectra with 
different spectral features, creating a 2D image of the investigated tissue surface. 
 
Fig. 4. Development of the Raman classification model for BCC. a) annotation of Raman 
spectra based on histopathology following k means clustering of Raman spectra collected by 
raster scanning; Scale bar: 0.5mm. b) Selected Raman spectra at the location indicated by 
arrows and coloured coded symbols in the annotated Raman map and circles in the adjacent 
H&E image. 
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K-means clustering can be controlled by selecting the number of clusters it generates. The 
k- means image that is generated can be compared to the adjacent histopathological section 
and can be used to annotate a large number of spectra with the correct tissue class (Fig. 4(a)). 
Figure 4(b) presents typical Raman spectra of skin tissue (measurement locations in the tissue 
indicated by arrows), which contained typical spectral features of skin tissue (Raman bands 
assigned to proteins, nucleic acids and lipids) [19]. 
The Raman spectra of BCC were characterized by intense bands corresponding to DNA 
(788 cm−1, 1098 cm−1) [18] compared with other tissue structures. The Raman spectra of 
dermis were dominated by the bands assigned to collagen at 851 and 950 cm−1 and by the 
Amide III band [18]). Following this procedure, the Laboratory instrument was utilized to 
scan 50 tissue samples from 30 patients, which were then processed and used in the 
construction of the spectral classifier. In order to obtain a diagnosis model for BCC, several 
Raman feature selection and classification models were developed, and their performance 
estimated first by 5-fold cross-validation. Although it is common to use principal component 
analysis (PCA) for feature selection, PCA tends to also include small spectral features that 
often can be at the same level or lower than variations between instruments. Because our aim 
was to transfer the Raman classification model from the Laboratory Instrument on the 
Prototype device, we decided to manually select spectral features (areas of Raman bands) that 
could be reliably measured and showed differences between classes larger than inter-
instrument variations. The highest performance for BCC detection was obtained when 
utilizing an Artificial Neural Network with 20 nodes in a single hidden layer with 13 spectral 
features. The average Raman spectra of the main tissue types included in the classification 
models are presented in Fig. 5(a): BCC, dermis, inflammation, epidermis (including hair 
follicles), muscle, fat (including sebaceous glands). The dye used by surgeons to mark the 
edges of the tissue can be easily identified by the several specific Raman bands at 680 cm−1, 
748 cm−1, 1144 cm−1 and 1528 cm−1. Given the spectral similarities between the Raman 
spectra of epidermis, muscle and inflammation, these spectra were grouped into a single class 
(labelled “EMI”) in order to simplify the classification model. 
 
Fig. 5. Development of the Raman classification model for BCC. a) Average Raman spectra of 
BCC, healthy skin tissue structures and surgical dye. The spectral features selected for the 
ANN classifier are highlighted (red lines represent the local baseline); b) confusion matrix for 
the 5-fold cross validation on the training set of samples measured on the Laboratory 
instrument. Class EMI includes epidermis, muscle and inflammation. 
The spectral features used as the input for the classification models were calculated as the 
areas of selected Raman bands that provided stable classification of BCC: 675 cm−1, 680 
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cm−1, 786 cm−1, 870 cm−1, 906 cm−1, 944 cm−1, 952 cm−1, 1092 cm−1, 1144 cm−1, 1298 cm−1, 
1376 cm−1, 1528 cm−1, 1744 cm−1. The confusion matrix obtained by 5-fold cross-validation 
(Fig. 5(b)) indicates that BCC can be discriminated from all other tissue types with overall 
87.7% sensitivity and 98.4% specificity. Whilst the classification model obtained > 98.7% 
sensitivity and specificity for dermis and fat, it correctly distinguished BCC from the EMI 
class (epidermis, inflammation and muscle) in ~89.2% of spectra. 
3.1.3 Criterion for MSH diagnosis at sample level 
Based on the estimated performance of the AF imaging analysis algorithms and the Raman 
spectroscopy classifier, as well as on certain simplifying assumptions (see below), we 
investigated the statistically optimal criterion (uniformly most powerful test) for deciding if a 
sample is BCC positive or negative. Namely, given a threshold Nth on the number NBCC of 
BCC-labeled segments in the MSH diagnosis image, the criterion is to call the sample “BCC-
positive” if NBCC≥Nth, and “BCC-negative” otherwise (i.e. if NBCC<Nth). To derive the 
necessary expressions we simplified the two-round rule for labelling a segment as follows: a 
segment is labelled as BCC if and only if at least two spectra are (individually) classified as 
BCC. Similarly, we assumed the number of Raman spectra per segment Nsampling(i) to be the 
same for all segments and equal to Nmin = 5. 
Estimating the “hit rate” as 0.6 and the per spectrum sensitivity and specificity as 81.8% 
and 96.3%, respectively, we obtained the predicted per segment 81.94% sensitivity and 
98.73% specificity. Using the number of non-BCC segments in the sample Nsampling,nonBCC = 
150, and the above per segment specificity estimate, the corresponding per sample specificity 
estimates was 95.65% when Nth = 5. Using the above per segment sensitivity estimate and 
specifying, and considering the worst case scenario when the samples has single BCC 
segment (Nsampling,BCC = 1), the corresponding per sample sensitivity was 11.03% when Nth = 
5. Being estimated for samples with a single BCC segment, these performance characteristics 
are overly pessimistic since BCC tumours typically spread over several segments in the AF 
image. For example, infiltrative BCCs typically consist of tens of microscopic (50-200μm) 
tumour regions. Thus, if we considered a more realistic case where the BCC is present in 10 
segments, using Nth = 5 leads to the per sample sensitivity and specificity of 99.93% and 
95.65%, respectively. 
Note that any sample containing non-BCC segments can have amongst its NBCC detections 
false alarms. Thus, even if such a sample contains BCC segments and is diagnosed to be 
“BCC-positive” (NBCC≥Nth), this does not mean that all of its NBCC detections, nor even Nth of 
them, are necessarily true positive. In the extreme case a BCC sample can be diagnosed as 
BCC while all of its NBCC detections are false positives. In practice, however, a sensible 
statistical test will need to assure that the chance of this happening is negligible. Using our 
test on samples with a single BCC segment, however, this probability (of correctly identifying 
such a sample as BCC based entirely on false positive segments) is 15.40% when Nth = 1, but 
reduces to 0.78% when Nth = 5. When a sample with more than 10 BCC segments, the 
probability drops below 10−6. 
It is important to realise that all of the above calculations are based on simplifying 
assumptions, such as that of statistical independence of test outcomes from different 
segments, constant number of spectra per segment (and subsequently constant per segment 
performance characteristics). Thus, the above predictions may be overestimates of the real 
performance. Nevertheless, the above calculations provide a simple guidance for selecting the 
threshold Nth in order to allow an objective way of establishing the diagnosis based on an 
MSH image. Further improvement of performance may be achieved by allowing the threshold 
Nth to depend on additional parameters of the sample, including those which have been 
assumed to be constant in the above discussion. 
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3.2 Transferability of the algorithms on the automated MSH Prototype using 
independent samples 
After the optimisation of the MSH algorithms using the training set of samples measured on 
the Laboratory instrument, the algorithms were implemented on the fully automated 
Prototype. A set of 47 independent skin samples (of which 32 BCC positive) from 40 patients 
undergoing Mohs micrographic surgery was used to evaluate the performance of each step of 
the algorithm in order to assess the inter-instrument transferability. 
Figure 6(a) presents the analysed AF images of two typical skin samples containing BCC. 
The tumour regions have low AF intensity, and are correctly captured by the segmentation 
algorithms ( ρ = 0.64 and 0.65). The values of ε  were 0.46 and 0.42, indicating that the 
segments containing BCC also contained ~60% healthy tissue. 
 
Fig. 6. Transferability testing of the optimised models on the automated MSH Prototype. a) 
typical examples of AF images and segmentation results; Scale bars: 5mm. b) statistical 
analysis of the performance parameters ρ , ε , hit rate and number of BCC segments missed; 
c) confusion matrix of the Raman model applied on independent samples; d) 5-fold cross-
validation of the joint training and test sets as a function of patient numbers. 
                                                                                 Vol. 8, No. 12 | 1 Dec 2017 | BIOMEDICAL OPTICS EXPRESS 5761 
Nevertheless, the “Hit rate” for BCC was 78% for Sample 1 and 56% for Sample 2, with 
no segments containing BCC being missed. The analysis of the performance metrics ρ  and 
ε  for all independent samples indicated a slight decrease compared to the values measured 
for the training set, though at the border of statistical significance (two-tailed t-test p-value of 
0.07 and 0.04 respectively) (Fig. 6(b)). Nevertheless, the two parameters that influence 
directly the results of the MSH algorithm, the “Hit rate” and the number of missed BCC 
segments, are consistent with the training set. The median value of the “Hit rate” was 0.6 and 
the number of missed BCC segments per tissue sample ranged between 0 and 7 (0 median). 
The consistency of the results obtained for the independent test and training test indicate that 
the parameters related to AF image analysis optimised on the Laboratory instrument can be 
successfully transferred on the Prototype device. Figure 6(c) presents the confusion matrix for 
the independent test using the Raman classification model transferred on the Prototype 
instrument. The results confirm that BCC can be discriminated from dermis and fat with a 
97.7% sensitivity and 99.3% specificity, which are similar to cross-validation results on the 
laboratory instrument. However, the sensitivity for discrimination of BCC and the EMI class 
(epidermis, inflammation and muscle) dropped to 71%, indicating that inter-instrument 
variations can mask subtle spectral differences between BCC and the EMI class. 
 
Fig. 7. Comparison between MSH diagnosis (automated Prototype instrument) and the 
corresponding histopathology sections for typical skin layers excised during Mohs 
micrographic surgery. The diagnosis was based on the algorithm optimised on the training 
samples measured on the Laboratory Instrument. Sample 1 and 2 are BCC-positive and Sample 
3 is BCC-negative. Tumours are encircled in blue circles and false positive segments in 
Sample 3 are highlighted by black arrows (circles and arrows were added manually). 
Overall, the results indicate a sensitivity of 81.8%% and specificity of 92.5% for 
discriminating BCC from all other tissue types, an absolute 6% drop in both sensitivity and 
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specificity compared to the 5-fold cross-validation results on the training set. After the 
independent test, the training and test data sets were merged and new 5-fold cross-validation 
analysis was performed as a function of the size of the training set (mixed Laboratory and 
Prototype instrument) (Fig. 6(d)). 
3.3 Independent testing of MSH using the automated prototype instrument 
After individual testing of the AF and Raman algorithms using independent samples, the 
performance of the MSH Prototype was tested using new independent samples. The MSH 
algorithm was based on Fig. 1(b) and contained the AF image analysis algorithms and Raman 
classification model trained using the samples measured on the Laboratory instrument. 
Firstly, we tested the use of the threshold number Nth = 5 that would allow a binary 
diagnosis of a skin sample as “BCC-positive” or “BCC-negative”. Sample 1 in Fig. 7 is an 
example of a skin sample with a large BCC of ~2mm. In this case, the number of segments 
labelled as BCC by the MSH algorithm was >20, which is higher than Nth, and the sample 
was diagnosed “BCC-positive”. Sample 2 had 10 tumour regions, ranging between 100 μm to 
1mm in size. Therefore, this sample is close to the detection limit of the instrument. The MSH 
analysis detected 8 BCC segments (6 true-positives and 2 false-positive segments), leading to 
the “BCC-positive” diagnosis. For the BCC-clear sample in Fig. 7 (Sample 3), the MSH 
diagnosis labelled 7 small segments as BCC. Because the number of segments labelled BCC 
is higher than the proposed threshold Nth = 5, this sample was incorrectly diagnosed as “BCC-
positive” (false-positive). This result indicates that the predicted 95.65% specificity for the Nth 
= 5 threshold is likely to be an over-estimation, and suggests that the assumptions used in the 
calculations were too simplistic (i.e. ignore the correlation between the spectra in the 
samples). In addition, the calculations for the Nth considered only the first round of Raman 
measurements. In the second round, additional Raman spectra are collected for segments that 
contained at least 2 but less than 80% spectra classified as BCC in the first round. If any of 
the Raman spectra in the second round are classified as BCC, but still do not reach the 80% 
threshold to label the whole segment as BCC, the initial segment is divided into smaller 
segment. Therefore, the second round of Raman measurements may lead to additional smaller 
false-positive segments in the final MSH image. This effect can be observed in Fig. 7: most 
false positive segments in Sample 3 are smaller in size than the true positive segments in 
Samples 1 and 2. To take into consideration these factors, a new threshold value was set at Nth 
= 8. This new threshold would deliver the correct diagnosis for the samples presented in Fig. 
7, and Sample 2 would represent a case at the limit of detection (8 segments labelled as 
BCC). Using the new threshold of Nth = 8, our probabilistic model predicts to deliver 92.93% 
sensitivity and 99.93% specificity per tissue sample. 
Next, we evaluated the consistency of the MSH diagnosis by repeating the analysis three 
times on a set of three new samples (Fig. 8). We included typical skin samples with large 
BCC (>4mm) and small BCC (e.g. 0.5-2 mm), and a BCC-clear sample. Each repeat 
measurement included the full analysis protocol: loading the tissue in the measurement 
cassette and loading the cassette into the instrument. At the end of the analysis, the cassette 
was unloaded from the instrument and the sample moved in a Petri dish. The stability of the 
Raman classifier was also evaluated by using different integration times for the Raman 
measurements (1s, 2s and 3s respectively). For Sample 1, >20 BCC segments were detected 
covering the area of the tumour, and 6-8 false positive segments were found at the edges of 
the sample (likely to correspond to inflamed dermis and hair follicles). Based on the Nth = 8 
threshold, correct BCC-positive diagnosis was obtained for all repeat measurements. Sample 
2 represented a sample at the limit of detection as it contained only two main BCC regions. 
One region had a tumour of ~1mm and few additional microscopic tumours, while the second 
region had a main tumour of ~1.5mm surrounded by 12 microscopic tumours (size 100-
200μm). Nevertheless, the sample was correctly diagnosed as BCC-positive in all repeat 
measurements because the MSH image detected >12 BCC segments. 
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 Fig. 8. Consistency of MSH diagnosis using the automated Prototype instrument. Sample 1 
and 2 are BCC-positive and Sample 3 is BCC negative. Tumours are encircled in blue circles 
and false positive segments in Sample 3 are highlighted by black arrows (circles and arrows 
were added manually). 
All MSH images included >6 segments correctly classified as BCC, as well as 6-8 false 
positive segments, approximately 100-200μm in size. While the locations of the BCC 
segments were consistent for the three repeat measurements and in agreement with the 
histopathology slide, the false positive measurements were randomly distributed. For Sample 
3 the numbers of false positive segments in the MSH images (6, 1 and 3 corresponding to the 
1s, 2s and 3s integration time, respectively) were lower than the threshold Nth = 8. Thus, MSH 
provided the correct “BCC-negative” diagnosis in all repeat measurements. Similar to the 
other samples, the false positive segments were randomly located in the images, and were 
approximately 10-20μm in size (only one false positive segment reached ~100μm). 
The consistent diagnosis results confirm the high repeatability of the MSH diagnosis with 
respect to the process of tissue handling (loading/unloading of the tissue sample in the 
measurement cassette, loading/unloading of the cassette within the instrument) and 
insensitivity to positioning the tissue within the field of view of the instrument. When using 
Nth = 8, correct diagnosis was obtained for all samples, even for the shortest integration time 
of 1s per spectrum. For this measurements, the total analysis time was 35-45 minutes, which 
is similar to frozen section histopathology. Increasing the integration time for the Raman 
measurements to 2s and 3s led to longer analysis times (47-57 minutes and 72-78 minutes, 
respectively) but decreased the number of false positive segments. 
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Finally, we evaluated the performance of the automated Prototype device when operated 
by non-specialist spectroscopy users. The MSH diagnosis obtained by two clinical users was 
compared to the result obtained by a spectroscopy specialist, as well as the reference 
histopathology. MSH is based on automated measurement and analysis algorithms, and the 
quantitative diagnosis is presented in a colour-coded image, in which each colour corresponds 
to a tissue class. The final diagnosis at a tissue level is obtained by comparing the number of 
BCC classified segments in the MSH image with a threshold value Nth. Because the actual 
tissue analysis is user-independent, the user requires training only on tissue handling (few 
hours). To demonstrate this feature, three users carried out repeat MSH analysis on a new set 
of skin specimens excised during Mohs micrographic surgery. User 1 (R. Boitor) was 
specialist in Raman spectroscopy and was the main person developing the MSH algorithms. 
User 2 (S. Varma) was a Mohs surgeon, and User 3 (B. Salence) was a core medical trainee 
intending to pursue a speciality in dermatology. 
 
Fig. 9. Consistency of MSH diagnosis among different users. User 1: spectroscopy specialist 
(R. Boitor), User 2: Mohs surgeon (S. Varma) with 1 h training, User 3 (B. Salence): core 
medical trainee with interest in dermatology (BS) with 8 hours training. Tumours are encircled 
in blue circles and false positive segments in Sample 3 are highlighted by black arrows (circles 
and arrows were added manually). 
User 2 and 3 had no experience in Raman spectroscopy and had ~1 hour, respectively 8 
hours, training on tissue handling (load/unload tissue in cassette) and operation of the 
prototype instrument (load cassette in the instrument, input patient data, and start/stop 
analysis). 
Figure 9 presents the MSH results obtained by the three users, and compares the results 
with the reference histopathology slides. For the BCC-positive samples (Samples 1 and 2), 
the number of segments classified as BCC was higher than the threshold value Nth = 8 for all 
measurements, leading to correct “BCC-positive” diagnosis. For the BCC clear sample 
(Sample 3) analysed independently by User 1 and User 3, the number of false positive 
segments was 7 and 5, respectively, indicating consistent “BCC-negative” diagnosis. These 
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results highlight the advantage of MSH diagnosis in providing a reliable and quantitative 
diagnosis, even when the analysis was carried out by non-specialist users with training as 
short as 1 hour. This feature is important when considering the deployment of the technology 
in the clinic; non-specialist users can operate the devices and obtain valid and repeatable 
diagnosis of each resected tissue layer in order to confirm the completeness of tumour 
excision. This is a key advantage compared to conventional histopathology or alternative 
optical microscopy techniques based on structural imaging, where users require extensive 
training and experience in order to recognise specific structural and morphological features 
required for diagnosis. 
4. Conclusions 
In this paper we present a fully automated multimodal spectral histopathology (MSH) 
Prototype instrument for detection of residual tumor during surgery of basal cell carcinoma 
(BCC). The instrument has been designed to be used in a clinical environment and be 
operated by non-specialist users. First, the data acquisition and analysis algorithms were 
optimized on a manually-operated Laboratory instrument, and then successfully transferred 
on the automated Prototype. We demonstrate that accurate diagnosis of residual BCC can be 
obtained in an automated manner on a range of skin specimens excised during Mohs 
micrographic surgery. Typical acquisition times for tissue samples with areas of 2cm x 2cm 
was less than 60 minutes, allowing detection of tumors as small as 100 μm. Using a simple 
binary diagnosis protocol based on a threshold number of BCC detected segments in the MSH 
images (Nth = 8), the correct diagnosis was obtained for all samples, in three repeat 
measurements (confirmed by histopathology as the standard of reference). We also show that 
the instrument can be operated by non-specialist spectroscopy users, including one Mohs 
surgeon and one core medical trainee, after training in tissue handling and instrument 
operation of 1-8 hours. The MSH diagnosis obtained by the non-specialist users was 
consistent with the results obtained by the spectroscopy specialist user, and agreed with the 
diagnosis provided by histopathology. This is an important result considering that the 
intended users of the device are histopathology technicians, nurses or dermatology surgeons. 
This is the first fully-automated prototype instrument based on Raman spectroscopy for intra-
operative microscopic imaging of surgical margins during cancer surgery, suitable to be used 
by a non-specialist user in a clinical environment. The development of the prototype is an 
important step on the clinical translation path, as it will allow the testing of the multimodal 
spectral histopathology technique in a relevant clinical environment in order to evaluate its 
performance on a sufficiently large number of patients. 
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